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Abstract
Objective
This pilot study assessed the efficacy of a knee guard device, which used magnetophoresis
to transdermally deliver Glucosamine, Chondroitin and Hyaluronic Acid in a cohort of individ-
uals with prior knee injury. The aim was to determine if the change in physical function and
pain with the knee guard device was equivalent to the change produced by an established
topical NSAID formulation containing diclofenac sodium 1%.
Methods
A randomized, controlled, equivalence trial evaluated outcomes following treatment with the
knee guard device or NSAID formulation. The study recruited 114 male participants (aged
40–55 years). Participants were randomly allocated to wear the knee guard device or to use
a NSAID gel daily for two weeks. The primary outcomes were the knee injury osteoarthritis
function score (KOOS-F) and an aggregated function score (AFS). The lower extremity
functional scale (LEFS), pain numerical rating scale (PNRS), global rating of change
(GROC) and other KOOS scores were also evaluated.
Results
Multiple linear regression analyses indicated that there were no significant differences
between the interventions for changes in the primary outcomes of AFS and KOOS_F. The
95% confidence interval (-2.89 to 5.15) of the estimated treatment difference for KOOS-F
was within the lower (-5.61) and upper (5.61) bounds of the 7% equivalence margin for that
measure, The mean value for the AFS was within, but the 95% CI (-3.11 to 7.37) exceeded
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the 7% equivalence margin (-2.97 to 2.97) for that measure. There was a significant differ-
ence in PNRS, which favored the knee guard device.
Conclusion
The knee guard device demonstrated equivalence for the KOOS-F measure but not the
AFS measure of function over the two week trial period when compared to a widely available
NSAID gel that has been shown to be superior to placebo. The knee guard produced a
greater reduction in pain report (p = 0.002) than the NSAID gel. Users of the knee guard
device experienced more skin irritation than participants using the NSAID gel. Further
research is required to fully evaluate the therapeutic potential of this innovative treatment
approach.
Introduction
Osteoarthritis (OA) affects more people than any other joint disease and is a major source of
disability in developed countries [1, 2]. Knee OA is the second most common form of osteoar-
thritis with the prevalence ranging from 18–28% in over 55s in the United Kingdom [1]. Knee
injury appears to be an independent risk factor, particularly for unilateral knee OA [3] and
those with a documented history of knee injury have a greater than 5 fold increased risk of
developing knee OA [4]. The cohort with significant prior knee injury is therefore a key group
to target for interventions to prevent or limit the development of OA.
Given the steadily increasing economic and societal burden of OA there is an increased
focus on strategies to manage knee injuries and the development of OA. The first line of man-
agement for knee OA includes regular exercise and bodyweight reduction [5, 6] with the sec-
ond line being the use of medical/pharmaceutical agents such as simple analgesics, non-
steroidal anti-inflammatory drugs (NSAIDs) and medications such as duloxetine [7]. NSAIDs,
particularly oral dosage forms, are normally only used in patients with a relatively low risk pro-
file for those medications [7].
The use of compounds targeted to the synovial joint (hyaluronic acid) and articular carti-
lage (chondroitin and glucosamine) has emerged as an alternative to the symptomatic second
line strategies. Intra-articular injection of hyaluronic acid to maintain synovial fluid function
has been a treatment option for several years [8]. It remains controversial despite a systematic
review of meta-analyses [9] and expert consensus [10] indicating that it is a valuable treatment
for early knee OA. Chondroitin and glucosamine exert a beneficial effect on the metabolism of
different cell lines that are involved in the development of OA [11, 12]. They increase type II
collagen and proteoglycan synthesis in human articular chondrocytes, reduce the production
of some pro-inflammatory factors and proteases and improve the anabolic/catabolic balance
of the extracellular cartilage matrix [11, 12]. Clinical trials have reported some beneficial effects
of oral chondroitin and glucosamine with a small but significant reduction in the rate of
decline in joint space width and some symptomatic improvement [11]. These benefits have
been supported by international guidelines [13]. Concerns have been expressed however in
relation to the bioavailability of chondroitin and glucosamine due to extensive first pass
metabolism following oral administration [14].
Delivering hyaluronic acid, chondroitin and glucosamine transdermally could provide
improved bioavailability compared to oral administration, but they have physicochemical
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characteristics that are unfavorable for skin permeation [15–18]. Advanced delivery systems
are required to enhance their transdermal penetration. Magnetophoresis is such a delivery
technology that has been shown to enhance the skin penetration of drug and peptide molecules
and 20nm gold particles [19–22]. The knee guard device (OBJ Pty Ltd, Perth) is a patented
wearable knee support that uses magnetophoresis to enhance transdermal delivery of thera-
peutic compounds from topical applications beyond that of passive diffusion [23]. It has yet to
be tested as a treatment intervention in a human population, thus the reason for this pilot trial.
The knee guard device is applied to the anterior aspect of the knee joint. It contains replace-
able gel pods which release the Lubricen formulation with diamagnetic backing sheets that
enhance the transdermal permeation of gel constituents.
This pilot study assessed the efficacy of the knee guard device, which uses magnetophoresis
technology, in a cohort of individuals with prior knee injury who are at increased risk of devel-
oping OA [4]. The main aim of the study was to determine if the change in physical function
and pain with the knee guard device was equivalent to the change produced by an established
NSAID formulation containing diclofenac sodium 1%.
Materials and methods
A randomized, controlled, pilot equivalence trial design was used to evaluate outcome follow-
ing treatment with the knee guard device or the NSAID formulation in middle-aged males fol-
lowing knee injury. The trial was approved by the Medical Research Ethics Committee at the
University of Queensland (MREC #2014001527, 2nd February 2015) and the trial protocol was
posted on the Australia New Zealand Clinical Trials Register (ANZCTRN12615000345583).
Participants
The study recruited male participants aged between 40 and 55 years who were in good general
health and currently participating in regular physical activity (>2 hours per week), despite a
prior history of knee injury requiring arthroscopy surgery, and/or a prolonged history of
recurrent knee pain (>2/10 on pain numerical rating scale). Key exclusion criteria included:
patellofemoral joint dysfunction, significant ligamentous deficiency and a history of cardiac
disease, high blood pressure, asthma or diabetes.
Following initial expression of interest from volunteers, a preliminary telephone interview
was used to determine the participant’s general suitability for the study and to arrange an
appropriate time for testing. Screening questionnaires were completed by email and testing
was carried out at the St Lucia Campus of the University of Queensland.
Participants completed the Fitness Australia Adult Pre-Exercise Screening tool to deter-
mine their suitability for participation in the study [24]. Participants who met the inclusion
criteria, had no exclusion criteria and were classified as low risk on the Pre-Exercise Screening
Tool were asked to provide written informed consent prior to participating in the study.
Interventions
Participants were allocated to wear the knee guard device (OBJ Pty Ltd, Perth) or to use a
NSAID gel. The knee guard device incorporated a magnetophoretic backing and gel filled
pods (1 g gel) including Lubricen (a Therapeutic Goods Administration (TGA) approved for-
mulation including Glucosamine Sulphate 10mg, Chondroitin Sulphate 2.5mg, Hyaluronic
Acid 2.5mg and Menthol 40mg per gram). Participants were required to wear the knee guard
device for a period of 3–5 hours per day.
The NSAID gel was a commercially available formulation of diclofenac sodium (1%) that
was applied 4 times daily, following manufacturer’s recommendations. Participants were
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asked to apply 4 g of the gel 4 times daily and they were provided with a card which guided
them to apply a standard amount each time [25]. The diclofenac gel is a well-established symp-
tomatic treatment with pooled data from three randomized controlled trials demonstrating
that the diclofenac sodium gel formulation achieves superior outcomes in terms of pain, func-
tion and pain on movement when compared to placebo formulations in patients with knee
OA [26]. The difference between active treatment and vehicle control indicated small to
medium effect sizes for WOMAC pain (0.22), WOMAC function (0.25) and VAS rating of
pain on movement (0.205) [27]. A recent Cochrane review concluded that diclofenac was sig-
nificantly more effective than vehicle for reducing OA pain with a number need to treat
(NNT) of 9.8 (CI 7.1–16) for a 50% reduction in pain [28]. The gel was provided in plain tubes
without manufacturer logos. The duration of treatment was limited to two weeks in order to
comply with the standard clinical recommendations not to apply the NSAID gel on a daily
basis for more than two weeks.
Randomization and masking
Participants were randomly assigned (computer generated random assignment by an investi-
gator not involved in recruitment or data collection/analysis) on a 1:1 basis to either wear the
knee guard device or to use the diclofenac sodium (1%) gel over a two week period. A research
assistant who was not involved in the baseline screening or any of the outcome measurements
administered the randomized allocation and provided the knee guard device or diclofenac
sodium (1%) gel to the participant as per the randomization schedule. The research assistant
who took the physical outcome measures was blind to the allocated treatment. The participants
were not blind to their allocated intervention, but were instructed to not tell the research assis-
tant taking the physical measures which treatment they were using (reminded by the other
research assistant on arrival at the testing site). To facilitate the blinding of the research assis-
tant taking the physical outcome measures, the participant also wore a sleeve over both knees
at baseline and follow up.
Outcome measures
The primary and secondary outcomes were taken at baseline and the primary end point of 2
weeks. Baseline measures of height and weight were also obtained.
The primary outcomes were the knee injury osteoarthritis score (KOOS) function score
and an aggregated function score (AFS). Pain and function was evaluated using the KOOS
[29], which assesses a participant’s opinion about their knee and associated problems. It is
intended for use with knee injury that can result in post-traumatic OA. It consists of 5 sub-
scales; pain (KOOS-P), other symptoms (KOOS-S), function in daily living (KOOS-F), func-
tion in sport (KOOS-SP) and knee related quality of life (KOOS-Qol). The 5 subscales are
reported separately as a percentage score, with 0 representing extreme problems and 100 rep-
resenting no problems. It has high test retest reliability (ICC >0.75) [30]. The test was admin-
istered in a paper and pencil format.
The aggregated function score was determined as the total time in seconds required to com-
plete: (a) 10 m shuttle run, (b) modified Balsolm agility run, (c) stair climb, and (d) 20 step
down-up. For the 10 m shuttle run, two marks were placed on a straight runway 10 m apart.
Two 0.5 kg weight bags were placed at the 10 m mark. The participant was asked to run as fast
as possible from the starting line to the 10 m mark, pick up a bag, return the bag to the ground
behind the starting line, run back to the 10 m mark, pick up the 2nd bag and bring it back to
the start line. The modified Balsom agility run requires the participant to negotiate a 12 m
course with 5 gates that required two changes of direction and two turns, as rapidly as possible.
Trial comparing magnetic transdermal patch and traditional NSAID
PLOS ONE | https://doi.org/10.1371/journal.pone.0211999 February 22, 2019 4 / 13
The original Balsolm agility test was 15m in length, which was reduced in this study due to
space restriction for safe execution of the test. The stair climb required the participant to
descend and ascend a flight of 20 stairs, with a landing half way down and at the bottom of the
stairs. The participant was required to touch every step and to move as fast as possible without
using the hand rail or any support. The step down-up test required the participant to step
down and up from a 15 cm block 20 times using the affected limb while keeping the unaffected
knee fully extended. The sole and heel of the unaffected leg had to touch the ground and the
top of the block each time. All these tests were repeated twice with a 3 min rest interval and the
best time recorded. To minimize risk of injury all participants warmed up by completing 5
min stationary cycling at 11–13 RPE followed by 5 min of dynamic mobility drills that imitated
the changes of direction and physical demands required during the physical function tests.
The secondary outcomes were the additional KOOS measures, the lower extremity func-
tional scale (LEFS) and a pain numerical rating scale (PNRS). The LEFS is a 20-item question-
naire with responses scored on a 5 point scale where 0 was unable to do/extremely difficult
and 4 was no difficulty. The maximum score is 80 and 9 has been calculated as a minimum
level of detectable change [31]. The PNRS is an 11 point scale with 0 being no pain and 10
being worse pain imaginable. Participants were asked to rate their worst level of pain as a
whole number over the past week.
A global rating of change score (GROC), compliance and adverse events with treatment, as
well as satisfaction with treatment were collected at 2 weeks. Participants rated how their con-
dition had changed from baseline to follow up on a 7 point GROC scale where 1 corresponded
to much worse, 7 to much better and 4 was no change (or the same). The GROC was dichoto-
mized with scores greater than 4 representing an improvement (i.e., 5 a little better, 6 better or
7 much better) and scores less than 5 being no change or worse.
Participants completed study diaries, in which they answered questions on compliance to
treatment, satisfaction with their knee, and on adverse events. The compliance question asked
the participant to rate compliance on a 5 point scale, where 4 was full compliance, 3 was mostly
compliant (>75% of treatment accomplished), 2 was complied with at least 50% of treatment,
1 was complied with less than 50% and 0 was not compliant at all (did not use treatment). Sat-
isfaction was rated by asking participants to answer yes or no to the question, ‘Is your current
level of pain satisfactory when you consider your level of activity and general function?’
Adverse events were determined by asking participants each week (by phone when they
were not physically being tested) if they had encountered any issue (yes or no) during the prior
week intervention period. If the participant indicated yes they were asked to comment/
describe further on the nature of the issue. The comments were then categorized on a 4 point
scale according to severity, with 3 indicating skin breakdown (e.g., blistering, raw, breakdown
of the skin etc.), 2 indicating minor changes in the skin condition (e.g., dry, flaky, red or rash),
1 indicating symptoms of altered sensation (e.g., itchy, heat, tingling) and 0 indicating no reac-
tion at all.
Data analysis
It was determined a priori (G�Power, Heinrich Hein University, Dusseldorf, Germany) using
a simple pairwise comparison (t-test) that a sample size of 114 participants would be required
to determine a pair-wise 7% equivalence rate on the KOOS-F (physical function) with an 11%
Standard Deviation (SD) assuming 90% power, 95% confidence interval (two sided) and a 10%
drop out rate [26].
We used Stata 14/SE (StatCorp, College Station, TX) to conduct the statistical analysis. Sta-
tistical analyses between groups were performed using intention-to-treat. Prior to conducting
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any analysis, the collected data were examined for missing values. Collinearity of the covariates
(potential confounders) was assessed before including them in the multivariable modelling for
testing the hypotheses. To examine whether the change (measured using a pre-post change
score) in primary and secondary outcomes between the two interventions were comparable,
multiple linear regression modeling was used. This modeling compared the equivalence of the
two interventions, adjusted for the effects of baseline function and other potential confound-
ers. Potential confounders included BMI and pre-existing pain levels, as they are related to
functional impairment (the primary outcome) [32].
The AFS was reduced to the aggregate of 3 tests: 10 m shuttle, Balsom agility run and stair
climb, because the step down-up was unable to be completed by 20 participants (due to pain).
An alpha level of 0.05 was considered significant in the final modelling. The group data are
presented as means and standard deviations, while the between group differences are pre-
sented in the form of regression coefficients and their 95% confidence intervals as derived
from the regression models. The residuals of the fitted models were examined to ensure that
all required assumptions were met. In the event of non-normally distributed residuals, appro-
priate transformation was implemented on the outcome variables in order to implement
appropriate parametric statistical analyses.
Results
One hundred and fourteen male participants enrolled between 113th July and 4th December
2015, with the last follow up on the 22nd of December 2015. Participants were recruited
through a media campaign (Facebook, magazines, newspaper, radio advertisements) in the
Brisbane metropolitan area during 2015. The participant flow chart shows the respondents to
the advertising campaign, the reasons for exclusion at the various stages, numbers allocated
and then numbers followed up (Fig 1). All participants completed the AFS and KOOS at base-
line while 99 and 109 completed the follow-up assessments with attrition rates being 13% and
4% respectively. The loss to follow up was equally distributed between the groups (i.e., AFS 7/
57 & 8/57 for the knee guard device and NSAID gel respectively; likewise 2/57 & 3/57 for
KOOS). The median follow up time was 14 days (IQR: 14 to 16). The two groups were compa-
rable at baseline for age (mean (SD): 47.7 (4.4) and 48.4 (4.8) years) and BMI (28.2 (3.8) and
29 (3.5) kg/m2).
Primary outcomes
Multiple linear regression analyses indicated that there were no significant differences between
the interventions for changes in the primary outcomes KOOS-F (p = 0.58) and AFS (p = 0.43),
The between group differences and their confidence intervals (Table 1), when corrected for
BMI and baseline pain intensity, are near null with confidence intervals containing 0, which
infers equivalence between the two treatments.
In order to further evaluate equivalence we calculated the 7% equivalence rate on the
KOOS-F from the NSAID group and its 95% confidence interval. The equivalence margin was
computed as -5.61 and 5.61. Against this we compared the 95% CI of the intervention group.
The 95% confidence interval (-2.89 to 5.15) of the estimated treatment difference for KOOS-F
between treatments is within the lower (-5.61) and upper (5.61) bounds of the equivalence
margin, which suggests that the two treatments are comparable. The 7% equivalence margin
for the AFS from the NSAID group was -2.97 to 2.97. The mean difference was 2.13, which sits
within this equivalence margin. However, the CI for the estimated treatment difference for
AFS between treatments was -3.11 to 7.37, which exceeds the equivalence margin, indicating
considerable variability in the AFS response.
Trial comparing magnetic transdermal patch and traditional NSAID
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Fig 1. Knee guard trial cohort flow diagram.
https://doi.org/10.1371/journal.pone.0211999.g001
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Secondary outcomes
Multiple linear regression analyses indicated that there were no significant differences between
the interventions for the changes in KOOS-P (p = 0.13), KOOS-S (p = 0.67), KOOS-SP
(p = 0.87), and KOOS–QoL (p = 0.93). LEFS (β = -0.55, 95%CI: -4.32 to 3.22 p = 0.77) and the
GROC score (β = -0.13, 95%CI: -0.43 to 0.18, p = 0.42). The GROC score revealed improve-
ment at follow up in 38 (69%) of the knee guard group and 32 (59%) of the NSAID gel group
(Table 1). Chi-squared analysis indicated that there was no difference in the percentage of par-
ticipants who were improved with each intervention (p = 0.28).
There was a significant difference in PNRS, which favored the knee guard device (β = -1.16,
95%CI: 0.44 to 1.88 p = 0.002). At follow up, the knee guard device group mean (SD) was 3.91
(2.05) on the PNRS compared to 4.69 (2.51) for diclofenac sodium (1%) gel.
Participants self-report of compliance was not different between treatments with 52 (96%)
in each group indicating that they had completed at least 50% of the allocated treatment, but
only 25 (46%) and 16 (30%) in the knee guard device and NSAID gel groups respectively
reporting full compliance. Given that full compliance required participants to wear the knee
guard device for 5 hours each day and apply the NSAID gel 4 times each day the overall level
of compliance was considered satisfactory.
There was no significant difference in overall satisfaction between treatments with 33 (60%)
and 34 (64%) of the knee guard and NSAID gel groups reporting that they were satisfied.
Adverse events during the treatment period
Skin breakdown (13, 24%) and skin irritation (28, 51%) were present in significantly more
(p<0.05) of those who wore the knee guard device, with only 1 (2%) of the NSAID gel group
reporting skin break down (Table 2, Chi-square test).
Discussion
The knee guard device demonstrated equivalence for the KOOS function score over the two
week trial period when compared to a widely available NSAID gel that has been shown to be
Table 1. Group mean (SD) outcome data and between groups mean differences (95% CI, p value, sample size) unless otherwise stated.
Measure‘ Knee guard NSAID Mean diff (95% CI) p-value
Baseline 2 weeks Baseline 2 weeks
Primary
KOOS-F 76.71 (13.16) 82.18 (15.10) 77.80 (16.47) 80.17 (17.83) 1.13 (-2.89 to 5.15) 0.58
AFS3 (sec) 41.81 (8.25) 40.87 (8.95) 42.75 (10.83) 42.39 (11.46) -2.13 (-3.11 to 7.37) 0.43
Secondary
KOOS-P 66.47 (12.17) 72.17 (15.71) 66.37 (15.83) 69.90 (17.43) 3.18 (-0.91 to 7.27) 0.13
KOOS-S 64.60 (17.18) 68.17 (20.57) 65.66 (17.90) 68.45 (17.19) 1.28 (-4.57 to 7.13) 0.67
KOOS-Sp 53.96 (18.99) 62.80 (23.20) 48.20 (17.54) 55.93 (25.40) -0.29 (-3.89 to 3.30) 0.87
KOOS-QoL 41.71 (17.77) 48.09 (20.16) 44.69 (18.71) 49.81 (18.46) 0.18 (-4.24 to 4.61) 0.93
LEFS 60.06
(11.22)
61.68
(13.81)
57.96
(12.07)
59.94
13.83)
-0.55 (-4.32 to 3.22) 0.77
PNRS 5.78
(1.73)
3.91
(2.05)
5.65
(2.17)
4.69
(2.51)
-1.16 (-1.88 to -0.44) 0.002
GROC 38 (69%) 32 (59%) 0.28
‘Knee Injury Osteoarthritis Score (KOOS): function in daily living (KOOS-F), pain (KOOS-P), other symptoms (KOOS-S), function in sport (KOOS-SP), knee related
quality of life (KOOS-QoL), Lower extremity function scale (LEFS), pain numerical rating scale (PNRS), global rating of change expressed as number improved (%)
(GROC).
https://doi.org/10.1371/journal.pone.0211999.t001
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superior to placebo [26, 27]. The finding of equivalence was demonstrated by the 95% confi-
dence interval of the estimated treatment difference for KOOS-F being within the lower and
upper bounds of the equivalence margin for that measure, Equivalence was not demonstrated
for the AFS measure, primarily due to the large variability in the AFS response. The finding of
equivalence for the KOOS-F measure was further supported by small non-significant between
group differences across all outcome measures. This suggests that the device provides thera-
peutic improvements in function and pain that are potentially valuable for overweight (by
BMI), middle-aged males with a prior knee injury and a moderate level of pain (~6/10).
The observed effects occurred with 46% and 30% of the knee guard device and NSAID gel
groups, respectively completing all allocated treatment, although the majority of both groups
completed at least 50% of the allocated treatment. With approximately 60% of participants
indicating overall satisfaction with allocated treatment, there are grounds for further research
on optimal dosing regimens.
Treatments like the knee guard device and the NSAID gel are generally regarded as second
line treatments, but they are also useful in facilitating individuals to undertake first line treat-
ments such as specific exercise and physical activity. Over the short trial period of 2-weeks
of use of the knee guard device, there were positive changes on most of the outcomes. The
total AFS time improved by approximately 7 seconds (9.5%) and while there is no established
clinically meaningful difference, an improvement of this magnitude supports further consi-
deration as a physical activity adjunct. The recommended minimally important clinical
difference of 8–9 for the KOOS [33] was met by the KOOS-SP, which might be an indication
that the knee guard device will enable participation in physical activities that have a front line
role in managing early onset OA. The other scales of the KOOS did not reach a clinically
meaningful improvement, but showed tendencies towards improvement. This was not unan-
ticipated as the dimensions captured by the KOOS are more likely to show change over a lon-
ger treatment period. The secondary outcome of worst pain experienced in the previous week
changed by a clinically meaningful difference (1.88 points on an 11 point PNRS) in the knee
guard device group [34]. This was significantly greater than the change in PNRS for the
NSAID gel group.
The current study was the first for this device in humans and was limited to a 2-week inter-
vention period, primarily because that was the recommended maximum daily treatment
period for the NSAID gel. Whilst this study focused on short-term outcomes in terms of pain
and function the active components in the Lubricen formulation have the potential to posi-
tively influence the development of OA. The results of this pilot study indicate that there
would be value in conducting prospective studies to determine if regular exercise in combina-
tion with wearing the knee guard device was of benefit in delaying the onset of OA in this at
risk population.
A limitation of the study is that it was restricted to male participants within a tight age
range. The population chosen was based on a high likelihood of the symptoms for which the
intervention would be most applicable. The reader must take this into consideration when
considering the data in practice.
Table 2. Adverse events during the treatment period.
Skin reaction Knee guard device NSAID gel
Skin breakdown (e.g., blistering) 13 (23.6%) 1 (2%)
Minor skin irritation (e.g., dry, flaky, red or rash) 28 (50.9%) 0
Altered sensation (e.g., itchy, heat, tingling) 1 (1.8%) 0
None 13 (23.6%) 53 (98%)
https://doi.org/10.1371/journal.pone.0211999.t002
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The skin normally provides a significant barrier to the penetration of large molecular
weight molecules, however the use of magnetophoresis has been shown to significantly
improve skin penetration of both small molecules and larger 20 nm gold nanoparticles [19–
22]. Integration of the skin penetration technology into wearable devices, such as the knee
guard, to enhance the availability of biologically active molecules over prolonged periods of
time represents an entirely new therapeutic approach to the management of degenerative con-
ditions such as OA. The participants in the present study had not received a specific diagnosis
of OA and so there is considerable potential value in pursuing studies to test the value of the
knee guard device in patients with a diagnosis of early stage knee OA.
A concern arising from the trial was that there was a significantly greater number of partici-
pants with skin breakdown (24% v 2%) or some form of skin irritation (51% v 0%) in the knee
guard group compared to the NSAID gel group. The majority of these skin reactions were dis-
covered on the weekly contact by the research assistant and through evaluating participant dia-
ries. Subsequent research has further optimized the formulation to significantly reduce the risk
of skin irritation.
Conclusion
A magnetophoretic device that can administer key ground substance components through the
skin over the knee joint has been shown to achieve equivalent improvements in physical function
as measured by the KOOS function scale but not the AFS over 2 weeks when compared to a com-
mercially available NSAID gel. Pain rating improvements were better with the knee guard device.
This device has potential to facilitate participation in physical activity and exercise, which is an
effective first line treatment for individuals at risk of developing knee OA. Caution should be exer-
cised during the further development of this device because the device group reported substan-
tially more skin breakdown. This pilot trial provides a basis on which to pursue further research
to fully evaluate the therapeutic potential of this innovative treatment approach.
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